ReviewEuropean respiratory review : an official journal of the European Respiratory Society2018
Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.
Review in European respiratory review : an official journal of the European Respiratory Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 317 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Efficacy of Pirfenidone in Progressive Chronic Hypersensitivity Pneumonitis
ULtrasOund Applicability in the Assessment of Patients With fibRosing Interstitial Lung Disease (LORD): A Research Protocol of a Single Center, Real-life, Prospective Observational Study
Occupational and Environmental Exposures Analysis in Interstitial Lung Diseases: a Prospective Observational Study.
Who cites it
317 citing papers in PubMed, 6 syntheses or guidelines pooled it, 640 citations in OpenAlex.
- Impact of time to diagnosis in patients with progressive fibrotic ILD: a systematic review.BMJ open respiratory research · 2026Pooled it
- Health-related quality of life and health state utility value in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.Health and quality of life outcomes · 2025Pooled it
- Pooled it
- A systematic review of procedural and sampling techniques for cryobiopsy in interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease-A Systematic Review.Biomolecules · 2024Pooled it
- Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis.Advances in respiratory medicine · 2022Guideline
- Objective Effects and Patient Preferences for Ambulatory Oxygen in Fibrotic Interstitial Lung Disease With Isolated Exertional Hypoxaemia: A Placebo-Controlled 6-Minute Walk Test Study.Respirology (Carlton, Vic.) · 2025Trial
- Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.The European respiratory journal · 2022Trial
- Fibronectin's tensional state as a mechanical signature of fibrotic extracellular matrix in idiopathic pulmonary fibrosis models.Matrix biology plus · 2026Article
- Incidence and prevalence of connective tissue disease (CTD)-associated interstitial lung disease in the United States.Clinical rheumatology · 2026Article
- Diaphragmatic Ultrasound in Fibrosing Interstitial Lung Disease: A Systematic Review of Current Evidence.Diagnostics (Basel, Switzerland) · 2026Review
- Misdiagnosis of Behcet's disease lung involvement as pulmonary cryptococcosis on imaging: A case report.Medicine · 2026Article
- Lung ultrasound in UIP and NSIP: clinical and functional associations.BMC pulmonary medicine · 2026Article
- Dual pathology, dual burden: Functional impact of emphysema and fibrosis in Hypersensitivity Pneumonitis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Real-World Experience with Nintedanib in a Progressive Pulmonary Fibrosis Cohort.Medicina (Kaunas, Lithuania) · 2026Observational
- Positive physician perceptions of structured lung ultrasound (LUS) training in interstitial lung disease (ILD): a post-workshop survey study.Rheumatology international · 2026Article
- Real-World Data on Halting Radiographic Progression with Antifibrotics in Connective Tissue Disease-Associated Interstitial Lung Disease: A Two-Center Study from Hungary.Journal of clinical medicine · 2026Article
- Holistic Management of Pulmonary Fibrosis: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2026Review
- Diagnostic Utility of Serum Krebs von den Lungen-6 (KL-6) and Surfactant Protein-D (SP-D) Levels in Hypersensitivity Pneumonitis.La Medicina del lavoro · 2026Article
- A syndromic framework for progressive pulmonary fibrosis.Respiratory research · 2026Review
257 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 7 countries.
Funding
Abstract
Although these conditions are rare, a proportion of patients with interstitial lung diseases (ILDs) may develop a progressive-fibrosing phenotype. Progressive fibrosis is associated with worsening respiratory symptoms, lung function decline, limited response to immunomodulatory therapies, decreased quality of life and, potentially, early death. Idiopathic pulmonary fibrosis may be regarded as a model for other progressive-fibrosing ILDs. Here we focus on other ILDs that may present a progressive-fibrosing phenotype, namely idiopathic nonspecific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, connective tissue disease-associated ILDs (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.